Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 2, 2015, Pages 195-208

  Hua, Yinan ^a   Nair, Sreejayan ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Calpain; Cardiometabolic diseases; Caspase; Cathepsin; MMP

Indexed keywords

CALPAIN; CASPASE; CATHEPSIN; CELL PROTEIN; COLLAGENASE; ELASTASE; GELATINASE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PROTEINASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; PEPTIDE HYDROLASE; PROTEINASE INHIBITOR;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOMETABOLIC DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DEVELOPED COUNTRY; DIABETES MELLITUS; DYSLIPIDEMIA; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; PROTEIN QUALITY; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; ENZYMOLOGY; METABOLIC DISEASES; METABOLISM; PATHOPHYSIOLOGY;

ANIMALIA;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; MODELS, BIOLOGICAL; PEPTIDE HYDROLASES; PROTEASE INHIBITORS;

EID: 84919794346     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.032     Document Type: Review

References (260)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
3. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
4. Malik V.S., Willett W.C., Hu F.B. Global obesity: trends, risk factors and policy implications. Nat. Rev. Endocrinol. 2013, 9:13-27.
5. Springer S.C., Silverstein J., Copeland K., Moore K.R., Prazar G.E., Raymer T., Shiffman R.N., Thaker V.V., Anderson M., Spann S.J., Flinn S.K. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics 2013, 131:e648-e664.
6. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
7. Rawlings N.D., Tolle D.P., Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 2004, 32:D160-D164.
8. Yasmin, McEniery C.M., Wallace S., Dakham Z., Pulsalkar P., Maki-Petaja K., Ashby M.J., Cockcroft J.R., Wilkinson I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25:372.
9. Nenan S., Boichot E., Lagente V., Bertrand C.P. Macrophage elastase (MMP-12): a pro-inflammatory mediator?. Mem. Inst. Oswaldo Cruz 2005, 100(Suppl. 1):167-172.
10. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75:346-359.
11. Massova I., Kotra L.P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12:1075-1095.
12. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., Goldberg A.T., Zellner J.L., Crumbley A.J. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
13. Stewart J.A., Wei C.C., Brower G.L., Rynders P.E., Hankes G.H., Dillon A.R., Lucchesi P.A., Janicki J.S., Dell'Italia L.J. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J. Mol. Cell. Cardiol. 2003, 35:311-319.
14. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
15. Griffin M.O., Fricovsky E., Ceballos G., Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell Physiol. 2010, 299:C539-C548.
16. Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiol. Rev. 2003, 83:731-801.
17. Zatz M., Starling A. Calpains and disease. N. Engl. J. Med. 2005, 352:2413-2423.
18. Bukowska A., Lendeckel U., Bode-Boger S.M., Goette A. Physiologic and pathophysiologic role of calpain: implications for the occurrence of atrial fibrillation. Cardiovasc. Ther. 2010, 30:e115-e127.
19. Fougerousse F., Anderson L.V., Delezoide A.L., Suel L., Durand M., Beckmann J.S. Calpain3 expression during human cardiogenesis. Neuromuscul. Disord. 2000, 10:251-256.
20. Nozaki K., Das A., Ray S.K., Banik N.L. Calpain inhibition attenuates intracellular changes in muscle cells in response to extracellular inflammatory stimulation. Exp. Neurol. 2010, 225:430-435.
21. Thomas A., El Rouby S., Reed J.C., Krajewski S., Silber R., Potmesil M., Newcomb E.W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
22. Lakshmikuttyamma A., Selvakumar P., Sharma A.R., Anderson D.H., Sharma R.K. In vitro proteolytic degradation of bovine brain calcineurin by m-calpain. Neurochem. Res. 2004, 29:1913-1921.
23. Blomgren K., Zhu C., Wang X., Karlsson J.O., Leverin A.L., Bahr B.A., Mallard C., Hagberg H. Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"?. J. Biol. Chem. 2001, 276:10191-10198.
24. McGinnis K.M., Whitton M.M., Gnegy M.E., Wang K.K. Calcium/calmodulin-dependent protein kinase IV is cleaved by caspase-3 and calpain in SH-SY5Y human neuroblastoma cells undergoing apoptosis. J. Biol. Chem. 1998, 273:19993-20000.
25. Greenwood A.F., Jope R.S. Brain G-protein proteolysis by calpain: enhancement by lithium. Brain Res. 1994, 636:320-326.
26. Han Y., Weinman S., Boldogh I., Walker R.K., Brasier A.R. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J. Biol. Chem. 1999, 274:787-794.
27. Lin Y.C., Brown K., Siebenlist U. Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:552-556.
28. Kubbutat M.H., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 1997, 17:460-468.
29. Pariat M., Carillo S., Molinari M., Salvat C., Debussche L., Bracco L., Milner J., Piechaczyk M. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 1997, 17:2806-2815.
30. Kishimoto A., Mikawa K., Hashimoto K., Yasuda I., Tanaka S., Tominaga M., Kuroda T., Nishizuka Y. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J. Biol. Chem. 1989, 264:4088-4092.
31. Dwyer L.D., Miller A.C., Parks A.L., Jaken S., Malkinson A.M. Calpain-induced downregulation of activated protein kinase C-alpha affects lung epithelial cell morphology. Am. J. Physiol. 1994, 266:L569-L576.
32. Shumway S.D., Maki M., Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J. Biol. Chem. 1999, 274:30874-30881.
33. Inserte J., Barba I., Hernando V., Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc. Res. 2009, 81:116-122.
34. Mani S.K., Shiraishi H., Balasubramanian S., Yamane K., Chellaiah M., Cooper G., Banik N., Zile M.R., Kuppuswamy D. In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H314-H326.
35. Fushimi K., Nakashima S., Banno Y., Akaike A., Takigawa M., Shimizu K. Implication of prostaglandin E(2) in TNF-alpha-induced release of m-calpain from HCS-2/8 chondrocytes. Inhibition of m-calpain release by NSAIDs. Osteoarthr. Cart. 2004, 12:895-903.
36. Letavernier B., Zafrani L., Nassar D., Perez J., Levi C., Bellocq A., Mesnard L., Sachon E., Haymann J.P., Aractingi S., Faussat A.M., Baud L., Letavernier E. Calpains contribute to vascular repair in rapidly progressive form of glomerulonephritis: potential role of their externalization. Arterioscler. Thromb. Vasc. Biol. 2012, 32:335-342.
37. Sol-Church K., Picerno G.N., Stabley D.L., Frenck J., Xing S., Bertenshaw G.P., Mason R.W. Evolution of placentally expressed cathepsins. Biochem. Biophys. Res. Commun. 2002, 293:23-29.
38. Rawlings N.D., Morton F.R., Kok C.Y., Kong J., Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 2008, 36:D320-D325.
39. Sever S., Altintas M.M., Nankoe S.R., Moller C.C., Ko D., Wei C., Henderson J., del Re E.C., Hsing L., Erickson A., Cohen C.D., Kretzler M., Kerjaschki D., Rudensky A., Nikolic B., Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 2007, 117:2095-2104.
40. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., Chang J.M., Choi H.Y., Campbell K.N., Kim K., Reiser J., Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 2008, 14:931-938.
41. Goulet B., Baruch A., Moon N.S., Poirier M., Sansregret L.L., Erickson A., Bogyo M., Nepveu A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 2004, 14:207-219.
42. Hook V., Funkelstein L., Wegrzyn J., Bark S., Kindy M., Hook G. Cysteine cathepsins in the secretory vesicle produce active peptides: cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim. Biophys. Acta 2012, 1824:89-104.
43. Cheng X.W., Murohara T., Kuzuya M., Izawa H., Sasaki T., Obata K., Nagata K., Nishizawa T., Kobayashi M., Yamada T., Kim W., Sato K., Shi G.P., Okumura K., Yokota M. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am. J. Pathol. 2008, 173:358-369.
44. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., Lee-Rykaczewski E., Coleman L., Rieman D., Barthlow R., Hastings G., Gowen M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271:12511-12516.
45. Staun-Ram E., Miller A. Cathepsins (S and B) and their inhibitor cystatin C in immune cells: modulation by interferon-beta and role played in cell migration. J. Neuroimmunol. 2011, 232:200-206.
46. Stoch S.A., Wagner J.A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther. 2008, 83:172-176.
47. Friedrichs B., Tepel C., Reinheckel T., Deussing J., von Figura K., Herzog V., Peters C., Saftig P., Brix K. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 2003, 111:1733-1745.
48. Honey K., Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003, 3:472-482.
49. Chwieralski C.E., Welte T., Buhling F. Cathepsin-regulated apoptosis. Apoptosis 2006, 11:143-149.
50. Kominami E., Tsukahara T., Hara K., Katunuma N. Biosyntheses and processing of lysosomal cysteine proteinases in rat macrophages. FEBS Lett. 1988, 231:225-228.
51. Nishimura Y., Kawabata T., Yano S., Kato K. Inhibition of intracellular sorting and processing of lysosomal cathepsins H and L at reduced temperature in primary cultures of rat hepatocytes. Arch. Biochem. Biophys. 1990, 283:458-463.
52. Carmona E., Dufour E., Plouffe C., Takebe S., Mason P., Mort J.S., Menard R. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry 1996, 35:8149-8157.
53. Lecaille F., Choe Y., Brandt W., Li Z., Craik C.S., Bromme D. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry 2002, 41:8447-8454.
54. Kirschke H., Schmidt I., Wiederanders B. Cathepsin S. The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15). Biochem. J. 1986, 240:455-459.
55. Turk B., Dolenc I., Lenarcic B., Krizaj I., Turk V., Bieth J.G., Bjork I. Acidic pH as a physiological regulator of human cathepsin L activity. Eur. J. Biochem. 1999, 259:926-932.
56. Perdereau C., Godat E., Maurel M.C., Hazouard E., Diot E., Lalmanach G. Cysteine cathepsins in human silicotic bronchoalveolar lavage fluids. Biochim. Biophys. Acta 2006, 1762:351-356.
57. Serveau-Avesque C., Martino M.F., Herve-Grepinet V., Hazouard E., Gauthier F., Diot E., Lalmanach G. Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids. Biol. Cell. 2006, 98:15-22.
58. Lemaire R., Huet G., Zerimech F., Grard G., Fontaine C., Duquesnoy B., Flipo R.M. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br. J. Rheumatol. 1997, 36:735-743.
59. Cheng X.W., Obata K., Kuzuya M., Izawa H., Nakamura K., Asai E., Nagasaka T., Saka M., Kimata T., Noda A., Nagata K., Jin H., Shi G.P., Iguchi A., Murohara T., Yokota M. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006, 48:979-987.
60. Lecaille F., Bromme D., Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008, 90:208-226.
61. Bode W., Engh R., Musil D., Laber B., Stubbs M., Huber R., Turk V. Mechanism of interaction of cysteine proteinases and their protein inhibitors as compared to the serine proteinase-inhibitor interaction. Biol. Chem. Hoppe Seyler 1990, 371:111-118. (Suppl.).
62. Matsumoto K., Mizoue K., Kitamura K., Tse W.C., Huber C.P., Ishida T. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 1999, 51:99-107.
63. Helali A.M., Iti F.M., Mohamed I.N. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis. Curr. Drug Targets 2013, 14:1591-1600.
64. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996, 87:171.
65. Black R.A., Kronheim S.R., Sleath P.R. Activation of interleukin-1 beta by a co-induced protease. FEBS Lett. 1989, 247:386-390.
66. Yuan J., Shaham S., Ledoux S., Ellis H.M., Horvitz H.R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993, 75:641-652.
67. Walker N.P., Talanian R.V., Brady K.D., Dang L.C., Bump N.J., Ferenz C.R., Franklin S., Ghayur T., Hackett M.C., Hammill L.D., et al. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer. Cell 1994, 78:343-352.
68. Wang L., Miura M., Bergeron L., Zhu H., Yuan J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994, 78:739-750.
69. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
70. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
71. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., Mann M., Krammer P.H., Peter M.E., Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
72. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
73. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
74. Stephanou A., Brar B., Liao Z., Scarabelli T., Knight R.A., Latchman D.S. Distinct initiator caspases are required for the induction of apoptosis in cardiac myocytes during ischaemia versus reperfusion injury. Cell Death Differ. 2001, 8:434-435.
75. Chowdhury I., Tharakan B., Bhat G.K. Caspases - an update. Comp. Biochem. Physiol. B: Biochem. Mol. Biol. 2008, 151:10-27.
76. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
77. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997, 16:6914-6925.
78. Xu G., Cirilli M., Huang Y., Rich R.L., Myszka D.G., Wu H. Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature 2001, 410:494-497.
79. Martinon F., Hofmann K., Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr. Biol. 2001, 11:R118-R120.
80. Weber C.H., Vincenz C. The death domain superfamily: a tale of two interfaces?. Trends Biochem. Sci. 2001, 26:475-481.
81. Orth K., O'Rourke K., Salvesen G.S., Dixit V.M. Molecular ordering of apoptotic mammalian CED-3/ICE-like proteases. J. Biol. Chem. 1996, 271:20977-20980.
82. Yang X., Chang H.Y., Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell 1998, 1:319-325.
83. Muzio M., Salvesen G.S., Dixit V.M. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J. Biol. Chem. 1997, 272:2952-2956.
84. Duan H., Chinnaiyan A.M., Hudson P.L., Wing J.P., He W.W., Dixit V.M. ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem. 1996, 271:1621-1625.
85. Zhou Q., Snipas S., Orth K., Muzio M., Dixit V.M., Salvesen G.S. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem. 1997, 272:7797-7800.
86. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 1997, 326(Pt 1):1-16.
87. Chang H.Y., Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 2000, 64:821-846.
88. Ray C.A., Black R.A., Kronheim S.R., Greenstreet T.A., Sleath P.R., Salvesen G.S., Pickup D.J. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992, 69:597-604.
89. Tewari M., Dixit V.M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 1995, 270:3255-3260.
90. Stegh A.H., Peter M.E. Apoptosis and caspases. Cardiol. Clin. 2001, 19:13-29.
91. Nalepa G., Zukowska-Szczechowska E. Caspases and apoptosis: die and let live. Wiad. Lek. 2002, 55:100-106.
92. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291:113-135.
93. Dai H., Korthuis R.J. Mast cell proteases and inflammation. Drug Discov. Today Dis. Models 2011, 8:47-55.
94. Pham C.T. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 2006, 6:541-550.
95. Samara C., Tavernarakis N. Calcium-dependent and aspartyl proteases in neurodegeneration and ageing in C. elegans. Ageing Res. Rev. 2003, 2:451-471.
96. Artal-Sanz M., Tavernarakis N. Proteolytic mechanisms in necrotic cell death and neurodegeneration. FEBS Lett. 2005, 579:3287-3296.
97. Han Y.P. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S88-S91.
98. Eddy A.A. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb. Haemost. 2009, 101:656-664.
99. Papazafiropoulou A., Tentolouris N. Matrix metalloproteinases and cardiovascular diseases. Hippokratia 2009, 13:76-82.
100. Markmann A., Schafer S., Linz W., Lohn M., Busch A.E., Wohlfart P. Down-regulation of calpain 9 is linked to hypertensive heart and kidney disease. Cell. Physiol. Biochem. 2005, 15:109-116.
101. Fan D., Takawale A., Lee J., Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012, 5:15.
102. Paez Pereda M., Ledda M.F., Goldberg V., Chervin A., Carrizo G., Molina H., Muller A., Renner U., Podhajcer O., Arzt E., Stalla G.K. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J. Clin. Endocrinol. Metab. 2000, 85:263-269.
103. Death A.K., Fisher E.J., McGrath K.C., Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003, 168:263-269.
104. Uemura S., Matsushita H., Li W., Glassford A.J., Asagami T., Lee K.H., Harrison D.G., Tsao P.S. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ. Res. 2001, 88:1291-1298.
105. Bouvet C., Gilbert L.A., Girardot D., deBlois D., Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005, 45:432-437.
106. Browatzki M., Larsen D., Pfeiffer C.A., Gehrke S.G., Schmidt J., Kranzhofer A., Katus H.A., Kranzhofer R. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J. Vasc. Res. 2005, 42:415-423.
107. Maquoi E., Munaut C., Colige A., Collen D., Lijnen H.R. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002, 51:1093-1101.
108. Negi S., Anand A. Atherosclerotic coronary heart disease-epidemiology, classification and management. Cardiovasc. Hematol. Disord. Drug Targets 2010, 10:257-261.
109. Liu P., Sun M., Sader S. Matrix metalloproteinases in cardiovascular disease. Can. J. Cardiol. 2006, 22(Suppl. B):25B-30B.
110. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
111. Zhu X., Wang Z., Hu C., Li Z., Hu J. Honokiol suppresses TNF-alpha-induced migration and matrix metalloproteinase expression by blocking NF-kappaB activation via the ERK signaling pathway in rat aortic smooth muscle cells. Acta Histochem. 2013, (in press).
112. Johnson J.L., Jackson C.L., Angelini G.D., George S.J. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1707-1715.
113. Orbe J., Fernandez L., Rodriguez J.A., Rabago G., Belzunce M., Monasterio A., Roncal C., Paramo J.A. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003, 170:269-276.
114. Hua Y., Xue J., Sun F., Zhu L., Xie M. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 2009, 83:18-25.
115. Newby A.C. Matrix metalloproteinase inhibition therapy for vascular diseases. Vasc. Pharmacol. 2012, 56:232-244.
116. Tan C., Liu Y., Li W., Deng F., Liu X., Wang X., Gui Y., Qin L., Hu C., Chen L. Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis 2014, 232:199-203.
117. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
118. Lemaitre V., O'Byrne T.K., Borczuk A.C., Okada Y., Tall A.R., D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J. Clin. Invest. 2001, 107:1227-1234.
119. Gough P.J., Gomez I.G., Wille P.T., Raines E.W. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 2006, 116:59-69.
120. Liang J., Liu E., Yu Y., Kitajima S., Koike T., Jin Y., Morimoto M., Hatakeyama K., Asada Y., Watanabe T., Sasaguri Y., Watanabe S., Fan J. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006, 113:1993-2001.
121. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004, 109:1408-1414.
122. Kuzuya M., Nakamura K., Sasaki T., Cheng X.W., Itohara S., Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1120-1125.
123. Silence J., Lupu F., Collen D., Lijnen H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1440-1445.
124. Tretjakovs P., Jurka A., Bormane I., Mikelsone I., Elksne K., Krievina G., Reihmane D., Verbovenko J., Bahs G. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clin. Chim. Acta 2012, 413:25-29.
125. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 2006, 47:C13-C18.
126. Koolwijk P., Sidenius N., Peters E., Sier C.F., Hanemaaijer R., Blasi F., van Hinsbergh V.W. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001, 97:3123-3131.
127. Suzuki Y., Nagai N., Yamakawa K., Kawakami J., Lijnen H.R., Umemura K. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 2009, 114:3352-3358.
128. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
129. Wang B.W., Chang H., Lin S., Kuan P., Shyu K.G. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc. Res. 2003, 59:460-469.
130. Rajavashisth T.B., Liao J.K., Galis Z.S., Tripathi S., Laufs U., Tripathi J., Chai N.N., Xu X.P., Jovinge S., Shah P.K., Libby P. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 1999, 274:11924-11929.
131. Magid R., Murphy T.J., Galis Z.S. Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc. J. Biol. Chem. 2003, 278:32994-32999.
132. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005, 112:1813-1824.
133. Chung A.W., Yang H.H., Sigrist M.K., Brin G., Chum E., Gourlay W.A., Levin A. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc. Res. 2009, 84:494-504.
134. Fang C., Wen G., Zhang L., Lin L., Moore A., Wu S., Ye S., Xiao Q. An important role of matrix metalloproteinase-8 in angiogenesis in vitro and in vivo. Cardiovasc. Res. 2013, 99:146-155.
135. Yao J., Xiong S., Klos K., Nguyen N., Grijalva R., Li P., Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 2001, 20:8066-8074.
136. Pintucci G., Yu P.J., Sharony R., Baumann F.G., Saponara F., Frasca A., Galloway A.C., Moscatelli D., Mignatti P. Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2-/-microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2). J. Cell. Biochem. 2003, 90:1015-1025.
137. Hollborn M., Stathopoulos C., Steffen A., Wiedemann P., Kohen L., Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:4360-4367.
138. Barness L.A., Opitz J.M., Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am. J. Med. Genet. A 2007, 143A:3016-3034.
139. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89:2595-2600.
140. Xu X., Hua Y., Nair S., Zhang Y., Ren J. Akt2 knockout preserves cardiac function in high-fat diet-induced obesity by rescuing cardiac autophagosome maturation. J. Mol. Cell Biol. 2013, 5:61-63.
141. Miksztowicz V., Siseles N., Fernandez Machulsky N., Schreier L., Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric 2012, 15:602-606.
142. Glowinska-Olszewska B., Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metab. Clin. Exp. 2007, 56:799-805.
143. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., Bocan T.M., Coker M.L., Etoh T., Spinale F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309.
144. Monti L.D., Galluccio E., Lucotti P., Setola E., Costa S., Fontana B., Oldani M., Merante D., Di Blasi P., Bosi E., Piatti P.M. Beneficial role of L-arginine in cardiac matrix remodelling in insulin resistant rats. Eur. J. Clin. Investig. 2008, 38:849-856.
145. Ban C.R., Twigg S.M., Franjic B., Brooks B.A., Celermajer D., Yue D.K., McLennan S.V. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res. Clin. Pract. 2010, 87:335-341.
146. Kosmala W., Plaksej R., Przewlocka-Kosmala M., Kuliczkowska-Plaksej J., Bednarek-Tupikowska G., Mazurek W. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int. J. Obes. 2008, 32:763-771.
147. Hayashi T., Sohmiya K., Ukimura A., Endoh S., Mori T., Shimomura H., Okabe M., Terasaki F., Kitaura Y. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 2003, 89:1236-1242.
148. Zhang H., Wu J., Dong H., Khan S.A., Chu M.L., Tsuda T. Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-beta signalling. Clin. Sci. 2014, 126:275-288.
149. Yao J., Xiong M., Tang B., Chen G., Liang M., Ma X., Wang Z., Wu Z. Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats. Eur. J. Cardiothorac. Surg. 2012, 42:e121-e127.
150. Rizzi E., Ceron C.S., Guimaraes D.A., Prado C.M., Rossi M.A., Gerlach R.F., Tanus-Santos J.E. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy. Exp. Mol. Pathol. 2013, 94:1-9.
151. Liu W., Wang X., Feng W., Li S., Tian W., Xu T., Song Y., Zhang Z. Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp. Mol. Pathol. 2011, 91:362-367.
152. Nagatomo Y., Carabello B.A., Coker M.L., McDermott P.J., Nemoto S., Hamawaki M., Spinale F.G. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H151-H161.
153. Lin J., Davis H.B., Dai Q., Chou Y.M., Craig T., Hinojosa-Laborde C., Lindsey M.L. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens. Res. 2008, 31:1225-1231.
154. Foronjy R.F., Sun J., Lemaitre V., D'Armiento J.M. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Hypertens. Res. 2008, 31:725-735.
155. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa K., Kinugawa S., Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006, 47:711-717.
156. Wang X., Chow F.L., Oka T., Hao L., Lopez-Campistrous A., Kelly S., Cooper S., Odenbach J., Finegan B.A., Schulz R., Kassiri Z., Lopaschuk G.D., Fernandez-Patron C. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009, 119:2480-2489.
157. Sakata Y., Yamamoto K., Mano T., Nishikawa N., Yoshida J., Hori M., Miwa T., Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004, 109:2143-2149.
158. Givvimani S., Tyagi N., Sen U., Mishra P.K., Qipshidze N., Munjal C., Vacek J.C., Abe O.A., Tyagi S.C. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch. Physiol. Biochem. 2010, 116:63-72.
159. Youn J.Y., Wang T., Cai H. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ. Res. 2009, 104:50-59.
160. 2+ influx- and phosphatidylinositol 3-kinase-mediated m-calpain activity for shear stress-induced endothelial cell polarity. Am. J. Physiol. Cell Physiol. 2007, 293:C1216-C1225.
161. Gonscherowski V., Becker B.F., Moroder L., Motrescu E., Gil-Parrado S., Gloe T., Keller M., Zahler S. Calpains: a physiological regulator of the endothelial barrier?. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2035-H2042.
162. Averna M., Stifanese R., De Tullio R., Salamino F., Bertuccio M., Pontremoli S., Melloni E. Proteolytic degradation of nitric oxide synthase isoforms by calpain is modulated by the expression levels of HSP90. FEBS J. 2007, 274:6116-6127.
163. Miyazaki T., Taketomi Y., Takimoto M., Lei X.F., Arita S., Kim-Kaneyama J.R., Arata S., Ohata H., Ota H., Murakami M., Miyazaki A. m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation 2011, 124:2522-2532.
164. Porn-Ares M.I., Saido T.C., Andersson T., Ares M.P. Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells. Biochem. J. 2003, 374:403-411.
165. Corada M., Mariotti M., Thurston G., Smith K., Kunkel R., Brockhaus M., Lampugnani M.G., Martin-Padura I., Stoppacciaro A., Ruco L., McDonald D.M., Ward P.A., Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9815-9820.
166. Cui G.M., Zhao Y.X., Zhang N.N., Liu Z.S., Sun W.C., Peng Q.S. Amiloride attenuates lipopolysaccharide-accelerated atherosclerosis via inhibition of NHE1-dependent endothelial cell apoptosis. Acta Pharmacol. Sin. 2013, 34:231-238.
167. Milligan S.A., Owens M.W., Grisham M.B. Inhibition of IkappaB-alpha and IkappaB-beta proteolysis by calpain inhibitor I blocks nitric oxide synthesis. Arch. Biochem. Biophys. 1996, 335:388-395.
168. Wang N., Chen W., Linsel-Nitschke P., Martinez L.O., Agerholm-Larsen B., Silver D.L., Tall A.R. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J. Clin. Invest. 2003, 111:99-107.
169. Lin C.Y., Lee T.S., Chen C.C., Chang C.A., Lin Y.J., Hsu Y.P., Ho L.T. Endothelin-1 exacerbates lipid accumulation by increasing the protein degradation of the ATP-binding cassette transporter G1 in macrophages. J. Cell. Physiol. 2011, 226:2198-2205.
170. von Wnuck Lipinski K., Keul P., Lucke S., Heusch G., Wohlschlaeger J., Baba H.A., Levkau B. Degraded collagen induces calpain-mediated apoptosis and destruction of the X-chromosome-linked inhibitor of apoptosis (xIAP) in human vascular smooth muscle cells. Cardiovasc. Res. 2006, 69:697-705.
171. Goodarzi M.O., Taylor K.D., Guo X., Quinones M.J., Cui J., Li Y., Saad M.F., Yang H., Hsueh W.A., Hodis H.N., Rotter J.I. Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study. Diabetes 2005, 54:1228-1232.
172. Horikawa Y., Oda N., Cox N.J., Li X., Orho-Melander M., Hara M., Hinokio Y., Lindner T.H., Mashima H., Schwarz P.E., del Bosque-Plata L., Horikawa Y., Oda Y., Yoshiuchi I., Colilla S., Polonsky K.S., Wei S., Concannon P., Iwasaki N., Schulze J., Baier L.J., Bogardus C., Groop L., Boerwinkle E., Hanis C.L., Bell G.I. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 2000, 26:163-175.
173. Garant M.J., Kao W.H., Brancati F., Coresh J., Rami T.M., Hanis C.L., Boerwinkle E., Shuldiner A.R. Atherosclerosis risk in communities, SNP43 of CAPN10 and the risk of type 2 diabetes in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2002, 51:231-237.
174. Leipold H., Knofler M., Gruber C., Haslinger P., Bancher-Todesca D., Worda C. Calpain-10 haplotype combination and association with gestational diabetes mellitus. Obstet. Gynecol. 2004, 103:1235-1240.
175. Lynn S., Evans J.C., White C., Frayling T.M., Hattersley A.T., Turnbull D.M., Horikawa Y., Cox N.J., Bell G.I., Walker M. Variation in the calpain-10 gene affects blood glucose levels in the British population. Diabetes 2002, 51:247-250.
176. Orho-Melander M., Klannemark M., Svensson M.K., Ridderstrale M., Lindgren C.M., Groop L. Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 2002, 51:2658-2664.
177. Cassell P.G., Jackson A.E., North B.V., Evans J.C., Syndercombe-Court D., Phillips C., Ramachandran A., Snehalatha C., Gelding S.V., Vijayaravaghan S., Curtis D., Hitman G.A. Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 2002, 51:1622-1628.
178. Wang J., Xu J., Finnerty J., Furuta M., Steiner D.F., Verchere C.B. The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 2001, 50:534-539.
179. Smith L.K., Rice K.M., Garner C.W. The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease. Mol. Cell. Endocrinol. 1996, 122:81-92.
180. Yang Y., Duan W., Zhou J., Yan J., Liu J., Zhang J., Jin Z., Yi D. Protective effects of adenosine on the diabetic myocardium against ischemia-reperfusion injury: role of calpain. Med. Hypotheses 2012, 79:462-464.
181. Shioda N., Moriguchi S., Shirasaki Y., Fukunaga K. Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. J. Neurochem. 2006, 98:310-320.
182. Heidrich F.M., Ehrlich B.E. Calcium, calpains, and cardiac hypertrophy: a new link. Circ. Res. 2009, 104:e19-e20.
183. Letavernier E., Perez J., Bellocq A., Mesnard L., de Castro Keller A., Haymann J.P., Baud L. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ. Res. 2008, 102:720-728.
184. Suryakumar G., Kasiganesan H., Balasubramanian S., Kuppuswamy D. Lack of beta3 integrin signaling contributes to calpain-mediated myocardial cell loss in pressure-overloaded myocardium. J. Cardiovasc. Pharmacol. 2010, 55:567-573.
185. Franchini K.G., Clemente C.F., Marin T.M. Focal adhesion kinase signaling in cardiac hypertrophy and failure. Braz. J. Med. Biol. Res. 2009, 42:44-52. (et al.).
186. Rabkin E., Aikawa M., Stone J.R., Fukumoto Y., Libby P., Schoen F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104:2525-2532.
187. Hua Y., Zhang Y., Dolence J., Shi G.P., Ren J., Nair S. Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes 2013, 62:498-509.
188. Curreri P.W., Kothari H.V., Bonner M.J., Miller B.F. Increased activity of lysosomal enzymes in experimental atherosclerosis, and the effect of cortisone. Proc. Soc. Exp. Biol. Med. 1969, 130:1253-1256.
189. Reddy V.Y., Zhang Q.Y., Weiss S.J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3849-3853.
190. Haidar B., Kiss R.S., Sarov-Blat L., Brunet R., Harder C., McPherson R., Marcel Y.L. Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux. J. Biol. Chem. 2006, 281:39971-39981.
191. Platt M.O., Ankeny R.F., Shi G.P., Weiss D., Vega J.D., Taylor W.R., Jo H. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1479-H1486.
192. Jormsjo S., Wuttge D.M., Sirsjo A., Whatling C., Hamsten A., Stemme S., Eriksson P. Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 2002, 161:939-945.
193. Sasaki T., Kuzuya M., Nakamura K., Cheng X.W., Hayashi T., Song H., Hu L., Okumura K., Murohara T., Iguchi A., Sato K. AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis 2010, 210:430-437.
194. Jaffer F.A., Kim D.E., Quinti L., Tung C.H., Aikawa E., Pande A.N., Kohler R.H., Shi G.P., Libby P., Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007, 115:2292-2298.
195. Li W., Kornmark L., Jonasson L., Forssell C., Yuan X.M. Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 2009, 202:92-102.
196. Rafatian N., Karunakaran D., Rayner K.J., Leenen F.H., Milne R.W., Whitman S.C. Cathepsin G deficiency decreases complexity of atherosclerotic lesions in apolipoprotein E-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H1141-H1148.
197. Sukhova G.K., Zhang Y., Pan J.H., Wada Y., Yamamoto T., Naito M., Kodama T., Tsimikas S., Witztum J.L., Lu M.L., Sakara Y., Chin M.T., Libby P., Shi G.P. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2003, 111:897-906.
198. Cheng X.W., Kikuchi R., Ishii H., Yoshikawa D., Hu L., Takahashi R., Shibata R., Ikeda N., Kuzuya M., Okumura K., Murohara T. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis 2013, 228:211-216.
199. Wang J., Liu Y., Li X., Peng D., Tan Z., Liu H., Qin Y., Xue Y. Zhong nan da xue xue bao. Yi xue ban. J. Cent. South Univ. Med. Sci. 2009, 34:130-134.
200. Liu Y., Li X., Peng D., Tan Z., Liu H., Qing Y., Xue Y., Shi G.P. Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am. J. Cardiol. 2009, 103:476-481.
201. Mirzaii-Dizgah I., Riahi E. Serum and saliva levels of cathepsin L in patients with acute coronary syndrome. J. Contemp. Dent. Pract. 2011, 12:114-119.
202. Eriksson P., Deguchi H., Samnegard A., Lundman P., Boquist S., Tornvall P., Ericsson C.G., Bergstrand L., Hansson L.O., Ye S., Hamsten A. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24:551-557.
203. Chiellini C., Costa M., Novelli S.E., Amri E.Z., Benzi L., Bertacca A., Cohen P., Del Prato S., Friedman J.M., Maffei M. Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. J. Cell. Physiol. 2003, 195:309-321.
204. Xiao Y., Junfeng H., Tianhong L., Lu W., Shulin C., Yu Z., Xiaohua L., Weixia J., Sheng Z., Yanyun G., Guo L., Min L. Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity. J. Clin. Endocrinol. Metab. 2006, 91:4520-4527.
205. Funicello M., Novelli M., Ragni M., Vottari T., Cocuzza C., Soriano-Lopez J., Chiellini C., Boschi F., Marzola P., Masiello P., Saftig P., Santini F., St-Jacques R., Desmarais S., Morin N., Mancini J., Percival M.D., Pinchera A., Maffei M. Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS One 2007, 2:e683.
206. Yang M., Sun J., Zhang T., Liu J., Zhang J., Shi M.A., Darakhshan F., Guerre-Millo M., Clement K., Gelb B.D., Dolgnov G., Shi G.P. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2202-2208.
207. Han J., Luo T., Gu Y., Li G., Jia W., Luo M. Cathepsin K regulates adipocyte differentiation: possible involvement of type I collagen degradation. Endocr. J. 2009, 56:55-63.
208. Taleb S., Lacasa D., Bastard J.P., Poitou C., Cancello R., Pelloux V., Viguerie N., Benis A., Zucker J.D., Bouillot J.L., Coussieu C., Basdevant A., Langin D., Clement K. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 2005, 19:1540-1542.
209. Jobs E., Riserus U., Ingelsson E., Helmersson J., Nerpin E., Jobs M., Sundstrom J., Lind L., Larsson A., Basu S., Arnlov J. Serum cathepsin S is associated with serum C-reactive protein and interleukin-6 independently of obesity in elderly men. J. Clin. Endocrinol. Metab. 2010, 95:4460-4464.
210. Arnlov J. Cathepsin S as a biomarker: where are we now and what are the future challenges?. Biomark. Med 2012, 6:9-11.
211. Taleb S., Cancello R., Poitou C., Rouault C., Sellam P., Levy P., Bouillot J.L., Coussieu C., Basdevant A., Guerre-Millo M., Lacasa D., Clement K. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J. Clin. Endocrinol. Metab. 2006, 91:1042-1047.
212. Huvenne V.A., Tyler P.A., Masson D.G., Fisher E.H., Hauton C., Huhnerbach V., Le Bas T.P., Wolff G.A. A picture on the wall: innovative mapping reveals cold-water coral refuge in submarine canyon. PLoS One 2011, 6:e28755.
213. Eguchi A., Feldstein A.E. Lysosomal cathepsin D contributes to cell death during adipocyte hypertrophy. Adipocyte 2013, 2:170-175.
214. Huang X., Vaag A., Carlsson E., Hansson M., Ahren B., Groop L. Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes. Diabetes 2003, 52:2411-2418.
215. Jobs E., Riserus U., Ingelsson E., Sundstrom J., Jobs M., Nerpin E., Iggman D., Basu S., Larsson A., Lind L., Arnlov J. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men. Diabetes Care 2013, 36:163-165.
216. Chen R.P., Ren A., Ye S.D. Correlation between serum cathepsin S and insulin resistance in type 2 diabetes. Exp. Ther. Med. 2013, 6:1237-1242.
217. Saito N., Mukaino S., Ogino K. Proceedings: triglyceride, lipid peroxidation, and cathepsin in the serum of spontaneously hypertensive rats. Jpn. Heart J. 1976, 17:345-347.
218. Wildenthal K., Mueller E.A. Lysosomal enzymes in the development and regression of myocardial hypertrophy induced by systemic hypertension. J. Mol. Cell. Cardiol. 1977, 9:121-130.
219. Rozek R.J., Kuo T.H., Giacomelli F., Wiener J. Proteolytic activities in hypertensive cardiomyopathy of rats. J. Mol. Cell. Cardiol. 1983, 15:173-187.
220. Suzuki H., Schaefer L., Ling H., Schaefer R.M., Dammrich J., Teschner M., Heidland A. Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am. J. Nephrol. 1995, 15:129-136.
221. Kirimura K., Takai S., Jin D., Muramatsu M., Kishi K., Yoshikawa K., Nakabayashi M., Mino Y., Miyazaki M. Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens. Res. 2005, 28:457-464.
222. Tang Q., Cai J., Shen D., Bian Z., Yan L., Wang Y.X., Lan J., Zhuang G.Q., Ma W.Z., Wang W. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J. Mol. Med. 2009, 87:249-260.
223. Sun M., Ouzounian M., de Couto G., Chen M., Yan R., Fukuoka M., Li G., Moon M., Liu Y., Gramolini A., Wells G.J., Liu P.P. Cathepsin-L ameliorates cardiac hypertrophy through activation of the autophagy-lysosomal dependent protein processing pathways. J. Am. Heart Assoc. 2013, 2:e000191.
224. Hua Y., Xu X., Shi G.P., Chicco A.J., Ren J., Nair S. Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy. Hypertension 2013, 61:1184-1192.
225. Imanishi T., Han D.K., Hofstra L., Hano T., Nishio I., Liles W.C., Gown A.M., Schwartz S.M. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/macrophage. Atherosclerosis 2002, 161:143-151.
226. Yao P.M., Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J. Biol. Chem. 2000, 275:23807-23813.
227. Perlman H., Pagliari L.J., Georganas C., Mano T., Walsh K., Pope R.M. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J. Exp. Med. 1999, 190:1679-1688.
228. Nhan T.Q., Liles W.C., Schwartz S.M. Role of caspases in death and survival of the plaque macrophage. Arterioscler. Thromb. Vasc. Biol. 2005, 25:895-903.
229. Nhan T.Q., Liles W.C., Chait A., Fallon J.T., Schwartz S.M. The p17 cleaved form of caspase-3 is present within viable macrophages in vitro and in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1276-1282.
230. Salvayre R., Auge N., Benoist H., Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. Biochim. Biophys. Acta 2002, 1585:213-221.
231. Geng Y.J. Biologic effect and molecular regulation of vascular apoptosis in atherosclerosis. Curr. Atheroscler. Rep. 2001, 3:234-242.
232. Nakagami H., Kaneda Y., Ogihara T., Morishita R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr. Diabetes Rev. 2005, 1:59-63.
233. Unger R.H., Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta 2002, 1585:202-212.
234. Yokoyama M., Yagyu H., Hu Y., Seo T., Hirata K., Homma S., Goldberg I.J. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J. Biol. Chem. 2004, 279:4204-4211.
235. Li S.Y., Liu Y., Sigmon V.K., McCort A., Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes. Metab. 2005, 7:448-454.
236. Barouch L.A., Gao D., Chen L., Miller K.L., Xu W., Phan A.C., Kittleson M.M., Minhas K.M., Berkowitz D.E., Wei C., Hare J.M. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ. Res. 2006, 98:119-124.
237. Lee S.D., Tzang B.S., Kuo W.W., Lin Y.M., Yang A.L., Chen S.H., Tsai F.J., Wu F.L., Lu M.C., Huang C.Y. Cardiac fas receptor-dependent apoptotic pathway in obese Zucker rats. Obesity 2007, 15:2407-2415.
238. Lu M.C., Tzang B.S., Kuo W.W., Wu F.L., Chen Y.S., Tsai C.H., Huang C.Y., Lee S.D. More activated cardiac mitochondrial-dependent apoptotic pathway in obese Zucker rats. Obesity 2007, 15:2634-2642.
239. Peterson J.M., Bryner R.W., Sindler A., Frisbee J.C., Alway S.E. Mitochondrial apoptotic signaling is elevated in cardiac but not skeletal muscle in the obese Zucker rat and is reduced with aerobic exercise. J. Appl. Physiol. 2008, 105:1934-1943.
240. Wang H.T., Liu C.F., Tsai T.H., Chen Y.L., Chang H.W., Tsai C.Y., Leu S., Zhen Y.Y., Chai H.T., Chung S.Y., Chua S., Yen C.H., Yip H.K. Effect of obesity reduction on preservation of heart function and attenuation of left ventricular remodeling, oxidative stress and inflammation in obese mice. J. Transl. Med. 2012, 10:145.
241. Panchal S.K., Poudyal H., Arumugam T.V., Brown L. Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J. Nutr. 2011, 141:1062-1069.
242. Ravassa S., Fortuno M.A., Gonzalez A., Lopez B., Zalba G., Fortuno A., Diez J. Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. Hypertension 2000, 36:1065-1071.
243. Rodriguez-Feo J.A., Fortes J., Aceituno E., Farre J., Ayala R., Castilla C., Rico L., Gonzalez-Fernandez F., Garcia-Duran M., Casado S., Lopez-Farre A. Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats. J. Hypertens. 2000, 18:307-315.
244. Der Sarkissian S., Marchand E.L., Duguay D., Hamet P., deBlois D. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc. Res. 2003, 57:775-783.
245. Lee Y.I., Cho J.Y., Kim M.H., Kim K.B., Lee D.J., Lee K.S. Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis. Eur. J. Appl. Physiol. 2006, 97:216-224.
246. Gonzalez A., Ravassa S., Loperena I., Lopez B., Beaumont J., Querejeta R., Larman M., Diez J. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J. Hypertens. 2007, 25:2148-2157.
247. Isodono K., Takahashi T., Imoto H., Nakanishi N., Ogata T., Asada S., Adachi A., Ueyama T., Oh H., Matsubara H. PARM-1 is an endoplasmic reticulum molecule involved in endoplasmic reticulum stress-induced apoptosis in rat cardiac myocytes. PLoS One 2010, 5:e9746.
248. Silvello D., Narvaes L.B., Albuquerque L.C., Forgiarini L.F., Meurer L., Martinelli N.C., Andrades M.E., Clausell N., Santos K.G., Rohde L.E. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers 2014, 19:49-55.
249. Shirakabe A., Asai K., Hata N., Yokoyama S., Shinada T., Kobayashi N., Mizuno K. Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int. Heart J. 2010, 51:404-410.
250. Opstad T.B., Pettersen A.A., Arnesen H., Seljeflot I. The co-existence of the IL-18+183 A/G and MMP-9-1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One 2013, 8:e74498.
251. Xu X., Wang L., Xu C., Zhang P., Yong F., Liu H., Wang J., Shi Y. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron. Artery Dis. 2013, 24:259-265.
252. Shi G.P., Sukhova G.K., Grubb A., Ducharme A., Rhode L.H., Lee R.T., Ridker P.M., Libby P., Chapman H.A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Invest. 1999, 104:1191-1197.
253. Manzano-Fernandez S., Januzzi J.L., Boronat-Garcia M., Bonaque-Gonzalez J.C., Truong Q.A., Pastor-Perez F.J., Munoz-Esparza C., Pastor P., Albaladejo-Oton M.D., Casas T., Valdes M., Pascual-Figal D.A. Beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J. Am. Coll. Cardiol. 2011, 57:849-858.
254. Patel P.C., Ayers C.R., Murphy S.A., Peshock R., Khera A., de Lemos J.A., Balko J.A., Gupta S., Mammen P.P., Drazner M.H., Markham D.W. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ. Heart Fail. 2009, 2:98-104.
255. Ankersmit H.J., Weber T., Auer J., Roth G., Brunner M., Kvas E., Moser B., Spreitzer S., Lassnig E., Maurer E., Hartl P., Wolner E., Boltz-Nitulescu G., Eber B. Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina. Heart 2004, 90:151-154.
256. Singh K.P., Jaffe A.S., Liang B.T. The clinical impact of circulating caspase-3 p17 level: a potential new biomarker for myocardial injury and cardiovascular disease. Futur. Cardiol. 2011, 7:443-445.
257. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 2007, 13:333-346.
258. Schulze C.J., Castro M.M., Kandasamy A.D., Cena J., Bryden C., Wang S.H., Koshal A., Tsuyuki R.T., Finegan B.A., Schulz R. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. Crit. Care Med. 2013, 41:2512-2520.
259. Duong le T. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bone Key Rep. 2012, 67.
260. Fischer U., Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005, 12(Suppl. 1):942-961.